Medicinova, Inc. MNOV

$1.31 -1.50% at last close

Analyst Consensus

Consensus Rating
Buy (3 Buy · 0 Hold · 0 Sell)
Average Price Target
$8.33
Implied Upside
+536.1%
Price Target Range
$6.00 – $10.00
Analysts (12 mo)
3

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-05-04
D. Boral CapitalJason Kolbert
Maintains Buy $9
2026-03-23
Maxim GroupJason McCarthy
Reinstates Buy $6
2026-03-16
HC Wainwright & Co.Lander Egaña Gorroño
Initiates coverage on Buy $10
2026-01-30
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-12-18
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-12-08
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-11-04
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-10-31
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-09-22
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-08-27
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-07-24
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-06-16
B. Riley SecuritiesMayank Mamtani
Maintains Buy $6 → $5
2025-04-09
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-03-14
D. Boral CapitalJason Kolbert
Maintains Buy $9
2025-02-21
D. Boral CapitalJason Kolbert
Maintains Buy $9
2024-12-06
D. Boral CapitalJason Kolbert
Maintains Buy $9
2024-12-02
D. Boral CapitalJason Kolbert
Initiates coverage on Buy $9
2021-03-10
Maxim GroupJason McCarthy
Initiates coverage on Buy $15
2020-03-13
B. Riley SecuritiesMayank Mamtani
Maintains Buy $22 → $11
2019-03-25
B. Riley SecuritiesDavid Buck
Assumes Buy $22
2018-03-28
B. Riley SecuritiesDavid Buck
Initiates coverage on Buy $22
2012-08-27
McNicoll Lewis Vlak
Terminates coverage on
2012-05-24
Ladenburg Thalmann
Maintains Buy $12 → $11

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$1.31
Market Cap
$65.46 million
52-Week Range
$1.17 $1.96
Average Volume
34K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.